Knight Therapeutics (GUD) Set to Announce Quarterly Earnings on Thursday

Knight Therapeutics (TSE:GUD) is set to release its earnings data before the market opens on Thursday, May 9th. Analysts expect Knight Therapeutics to post earnings of C$0.02 per share for the quarter.

Knight Therapeutics (TSE:GUD) last issued its earnings results on Thursday, March 21st. The company reported C($0.03) EPS for the quarter, missing analysts’ consensus estimates of C$0.02 by C($0.05). Knight Therapeutics had a negative net margin of 5.13% and a negative return on equity of 2.14%. The firm had revenue of C$74.20 million during the quarter, compared to analyst estimates of C$78.37 million.

Knight Therapeutics Stock Down 0.8 %

GUD opened at C$5.87 on Wednesday. The company has a market capitalization of C$593.87 million, a P/E ratio of -36.69, a P/E/G ratio of -1,013.50 and a beta of 0.49. The company has a debt-to-equity ratio of 9.25, a current ratio of 3.20 and a quick ratio of 1.79. The firm’s fifty day moving average price is C$5.55 and its two-hundred day moving average price is C$5.36. Knight Therapeutics has a fifty-two week low of C$4.35 and a fifty-two week high of C$5.95.

Insider Buying and Selling at Knight Therapeutics

In other news, insider Sime Armoyan sold 10,900 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of C$5.95, for a total transaction of C$64,855.00. Company insiders own 46.44% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GUD. Royal Bank of Canada upped their target price on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the company an “outperform” rating in a research note on Friday, March 22nd. Stifel Nicolaus upped their price objective on Knight Therapeutics from C$5.25 to C$5.40 and gave the company a “hold” rating in a research note on Wednesday, May 1st. Finally, Raymond James raised their target price on Knight Therapeutics from C$7.00 to C$7.50 and gave the stock an “outperform” rating in a research report on Wednesday, March 6th.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.